Dr. Douglas Flora, executive medical director at the Yung Family Cancer Center, highlighted the transformative role of artificial intelligence (AI) in enhancing oncology clinical trials during the Inaugural MiBA Community Summit. He outlined three key ways AI is revolutionizing clinical trial design and execution to improve efficiency and reduce costs.
Firstly, AI streamlines patient screening by quickly identifying suitable trial candidates, automating tasks traditionally handled by clinical staff. Secondly, AI accelerates early-phase drug development through in silico trials, enabling researchers to simulate and pinpoint effective therapeutic targets faster. This innovative approach significantly shortens the drug development timeline. Lastly, AI optimizes trial logistics, facilitating quicker patient enrollment and better tracking of treatment risks and benefits throughout the trial.
Dr. Flora emphasized that adopting AI technologies is crucial for refining clinical trial processes, thereby enhancing return on investment and advancing effective cancer treatments faster.
Source link
